Clinical Trial Update: A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the CAR-T therapy C-CAR039 in relapsed/refractory Non-Hodgkin lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• C-CAR039

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Non-Hodgkin's B-cell Lymphoma | Phase 1 | Status: COMPLETED